Screening for Chlamydia trachomatis in asymptomatic women in Hungary -: An epidemiological and cost-effectiveness analysis

被引:12
|
作者
Nyári, T
Nyári, C
Woodward, M
Mészáros, G
Deák, J
Nagy, E
Kovács, L
机构
[1] Univ Szeged, Dept Med Informat, H-6720 Szeged, Hungary
[2] Univ Szeged, Dept Obstet & Gynaecol, Szeged, Hungary
[3] Univ Szeged, Dept Clin Microbiol, Szeged, Hungary
[4] Univ Sydney, Inst Int Hlth, Sydney, NSW 2006, Australia
关键词
C. trachomatis infection; cost-effectiveness analysis; preventive strategy; risk factors;
D O I
10.1034/j.1600-0412.2001.080004300.x
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Background. A multicenter survey was carried out in order to determine the prevalence and risk factors for Chlamydia trachomatis infection in the population of asymptomatic: women in Hungary. Results were used to carry out a cost-effectiveness analysis of screening for chlamydial infection in women with asymptomatic genital infections. Methods. The non-amplified nucleic acid hybridization method (PACE 2 Gen-Probe) was used to diagnose C. trachomatis and Bayes' theorem was applied to assess the prevalence of the infection. Multiple logistic regression analysis was performed to differentiate the risk factors for chlamydial infections. Results. According to the test, the prevalence of Chlamydia trachomatis among 1300 pregnant women was 4.5%. The sensitivity and specificity of the test are estimated to be 70% and 99%. respectively. After Bayes' correction, the overall estimated prevalence of chlamydial infection was 5.1%. There were significant differences in proportions of chlamydial infection in different regions, and also in different age groups and different family status groups. The highest rate was for women aged below 20 years: 16.9%. Cost-effectiveness analysis, with associated sensitivity analysis was carried out for women aged below 20 years. Three screening strategies were compared: using the ELISA method, using amplified Gen-Probe method and no screening. The amplified Gen-Probe method was best provided, the infection prevalence exceeded 16.7%, the PID rate exceeded 24% and the probability of tubal infertility in untreated women exceeded 25%. Conclusion. We conclude that screening with amplified Gen-Probe assays (followed by treatment of positive patients) is the preferred screening strategy for young women in Hungary.
引用
收藏
页码:300 / 306
页数:7
相关论文
共 50 条
  • [1] A cost-effectiveness analysis of screening and treatment for Chlamydia trachomatis infection in asymptomatic women
    Genc, M
    Mardh, PA
    ANNALS OF INTERNAL MEDICINE, 1996, 124 (01) : 1 - 7
  • [2] Cost-effectiveness analysis of Chlamydia trachomatis screening in Dutch pregnant women
    Rours, G. I. J. G.
    Smith-Norowitz, Tamar Anne
    Ditkowsky, Jared
    Hammerschlag, Margaret R.
    Verkooyen, R. P.
    de Groot, R.
    Verbrugh, H. A.
    Postma, M. J.
    PATHOGENS AND GLOBAL HEALTH, 2016, 110 (7-8) : 292 - 302
  • [3] Epidemiology of Chlamydia trachomatis infection in women and the cost-effectiveness of screening
    Land, J. A.
    Van Bergen, J. E. A. M.
    Morre, S. A.
    Postma, M. J.
    HUMAN REPRODUCTION UPDATE, 2010, 16 (02) : 189 - 204
  • [4] COST-EFFECTIVENESS OF SCREENING FOR CHLAMYDIA TRACHOMATIS IN DUTCH PREGNANT WOMEN
    Rours, G. I. J. G.
    Verkooijen, R. P.
    Verbrugh, H. A.
    Postma, M. J.
    SEXUALLY TRANSMITTED INFECTIONS, 2011, 87 : A61 - A61
  • [5] Screening for Chlamydia trachomatis in asymptomatic women attending family planning clinics -: A cost-effectiveness analysis of three strategies
    Howell, MR
    Quinn, TC
    Gaydos, CA
    ANNALS OF INTERNAL MEDICINE, 1998, 128 (04) : 277 - +
  • [6] Cost effectiveness analysis of a population based screening programme for asymptomatic Chlamydia trachomatis infection in women
    Gupta, M
    Hernon, M
    Gokhale, R
    Ghosh, AK
    SEXUALLY TRANSMITTED INFECTIONS, 2002, 78 (01) : 76 - 76
  • [7] Screening for Chlamydia trachomatis in women 15 to 29 years of age:: A cost-effectiveness analysis
    Hu, D
    Hook, EW
    Goldie, SJ
    ANNALS OF INTERNAL MEDICINE, 2004, 141 (07) : 501 - 513
  • [8] The cost and cost-effectiveness of opportunistic screening for Chlamydia trachomatis in Ireland
    Gillespie, Paddy
    O'Neill, Ciaran
    Adams, Elisabeth
    Turner, Katherine
    O'Donovan, Diarmuid
    Brugha, Ruairi
    Vaughan, Deirdre
    O'Connell, Emer
    Cormican, Martin
    Balfe, Myles
    Coleman, Claire
    Fitzgerald, Margaret
    Fleming, Catherine
    SEXUALLY TRANSMITTED INFECTIONS, 2012, 88 (03) : 222 - 228
  • [9] Cost-effectiveness of a pharmacy-based screening for Chlamydia trachomatis
    van Bergen, JE
    Postma, MJ
    Peerbooms, PG
    Spangenberg, AC
    Tjen-A-Tak, J
    Bindels, PJ
    VALUE IN HEALTH, 2003, 6 (06) : 754 - 755
  • [10] The Cost-Effectiveness of Screening Men for Chlamydia trachomatis: A Review of the Literature
    Gift, Thomas L.
    Blake, Diane R.
    Gaydos, Charlotte A.
    Marrazzo, Jeanne M.
    SEXUALLY TRANSMITTED DISEASES, 2008, 35 (11) : S51 - S60